Claims for Patent: 5,968,979

Summary for Patent: 5,968,979

Title:	Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
Abstract:	Two new forms of prodrug for phenylacetate, of even congeners of phenylalkanoic acid and phenylalkenoic acids, which are the phenylalkanoic or phenylalkenoic esters of glycerol, or the ethyl esters of phenylalkanoic acid or phenylalkenoic acids. These forms of the drugs provide a convenient dosage form of the drugs. The prodrugs of the invention are useful to treat patients with diseases of nitrogen accumulation, patients with certain β-hemoglobinopathies, anemia, and cancer.
Inventor(s):	Saul W. Brusilow
Assignee:	Brusilow Enterprises LLC
Application Number:	US09/006,432
Patent Claims:	1. A method of treating a nitrogen metabolism disorder in a patient in need of such treatment, comprising administering to said patient an effective amount of a compound of formula (I) ##STR5## wherein R1, R2 and R3 are independently H, ##STR6## n is zero or an even number from 2-24 and m is an even number from 2-24, provided that at least one of R1, R2 and R3 is other than H. 2. A compound of formula I ##STR7## wherein R1, R2, and R3 are independently ##STR8## and n and m are an even number from 2 to 24. 3. A pharmaceutical composition comprising (a) a compound of formula I ##STR9## wherein R1, R2, and R3 are independently H, ##STR10## and n is zero or an even number from 2-24, m is an even number from 2-24, wherein at least one of R1, R2, and R3 is not H, and (b) a component selected from the group consisting of hydroxyurea and erythropoietin. 4. A pharmaceutical composition suitable for the treatment of nitrogen metabolism disorders, β-hemoglobinopathies, anemia or cancer comprising a compound of formula I ##STR11## wherein R1, R2, and R3 are independently ##STR12## n is zero or an even number from 2-24, and m is an even number from 2-24 and a pharmaceutically acceptable excipient. 5. A pharmaceutical composition suitable for the treatment of nitrogen metabolism disorders, β-hemoglobinopathies, anemia and cancer comprising ethyl esters of the formula II ##STR13## wherein R4 is Cm H2m-2 --CH2 --C6 H5 and m is an even number from 2-24, together with at least one pharmaceutically acceptable excipient. 6. A pharmaceutical composition suitable for the treatment of nitrogen metabolism disorders, β-hemoglobinopathies, anemia or cancer comprising a compound of formula I ##STR14## wherein R1, R2, and R3 are independently H, ##STR15## n is zero or an even number from 2-24, and m is an even number from 2-24, provided that at least one of R1, R2, and R3 is a compound of the formula ##STR16## and a pharmaceutically acceptable excipient. 7. A compound of the formula I ##STR17## wherein R1, R2, and R3 are independently H, ##STR18## and n is zero or an even number from 2-24, and m is an even number from 2-24, with the provisos that at least one of R1, R2, and R3 is not H, and that when n is 0 or 2, then one of R1, R2, and R3 is a compound of the formula ##STR19## 8. The compound of claim 7, wherein n is 0, 2, 4, or 6, and m is 2, 4, or 6. 9. A pharmaceutical composition suitable for the treatment of nitrogen metabolism disorders, β-hemoglobinopathies, anemia or cancer, comprising the compound of claim 7, and a pharmaceutically acceptable excipient. 10. The composition of claim 9, wherein n is 0, 2, 4, or 6, and m is 2, 4, or 6.